Evaluation of everolimus in renal cell cancer

Bibliography

• Kidney Cancer. American Cancer Society, 2013
   Google Scholar
• Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2009., in Institute NC. Vintage 2009 Populations, Bethesda, MD; 2011. Available from: http://seer.cancer.gov/csr/1975_2009_pops09/
   Google Scholar
• Motzer RJ, Bacik J, Murphy BA, et al. Interferon alfa as a comparative treatment for clinical trals of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96
   PubMed Web of Science ®Google Scholar
• Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23:832-41
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454-63
   PubMedGoogle Scholar
• Yang JC, Childs R. Immunotherapy for renal cell cancer. J Clin Oncol 2006;24:5576-83
   PubMed Web of Science ®Google Scholar
• Dosquet C, Coudert MC, Lepage E, et al. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res 1997;3:2451-8
   PubMed Web of Science ®Google Scholar
• Jacobsen J, Rasmuson T, Grankvist K, et al. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000;163:343-7
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Suzuki K, Koike H, et al. Prognostic significance of plasma placental growth factor levels in renal cell cancer: an association with clinical characteristics and vascular endothelial growth factor levels. Anticancer Res 2003;23:4953-8
   PubMed Web of Science ®Google Scholar
• Garcia JA, Rini BI. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin 2007;57:112-25
   PubMed Web of Science ®Google Scholar
• Inoki K, Guan KL. Complexity of the TOR signaling network. Trends Cell Biol 2006;16:206-12
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-101
   PubMed Web of Science ®Google Scholar
• Fingar DC, Richardson CJ, Tee AR, et al. mTOR controls cell cycle progression through its cell growth effectors S6K1and 4EBP1/eukaryotic translation factor 4E. Mol Cell Biol 2004;24:200-16
   PubMed Web of Science ®Google Scholar
• Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1a expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22:7004-14
   PubMed Web of Science ®Google Scholar
• Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006;12:122-7
   PubMed Web of Science ®Google Scholar
• Corradetti MN, Guan KL. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene 2006;25:6347-60
   PubMed Web of Science ®Google Scholar
• Williams LT. Signal transduction by the platelet-derived growth factor receptor. Science 1989;243:1564-70
   PubMed Web of Science ®Google Scholar
• Pantuck AJ, Seligson DB, Klatte T, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007;109:2257-67
   PubMed Web of Science ®Google Scholar
• Crespo JL, Hall MN. Elucidating TOR signaling and rapamycin action: lessons from Saccharomyces cerevisiae. Microbiol Mol Biol Rev 2002;66:579-91
   PubMed Web of Science ®Google Scholar
• Dancey JE. Inhibitors of the mammalian target of rapamycin. Expert Opin Investig Drugs 2005;14:313-28
   PubMed Web of Science ®Google Scholar
• Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335-48
   PubMed Web of Science ®Google Scholar
• Bjornsti MA, Houghton PJ. Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell 2004;5:519-23
   PubMed Web of Science ®Google Scholar
• Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005;120:747-59
   PubMed Web of Science ®Google Scholar
• Powis G, Kirkpatrick L. Hypoxia inducible factor-1 (alpha) as a cancer drug target. Mol Cancer Ther 2004;3:647-54
   PubMed Web of Science ®Google Scholar
• Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004;9(Suppl 5):10-17
   PubMedGoogle Scholar
• Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45
   PubMed Web of Science ®Google Scholar
• Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
   PubMed Web of Science ®Google Scholar
• Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9
   PubMed Web of Science ®Google Scholar
• Kodaki T, Woscholski R, Hallberg B, et al. The activation of phosphatidylinositol 3-kinase by Ras. Curr Biol 1994;4:798-806
   PubMed Web of Science ®Google Scholar
• Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002;14:381-95
   PubMed Web of Science ®Google Scholar
• deGraffenried LA, Friedrichs WE, Russell DH, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 2004;10:8059-67
   PubMed Web of Science ®Google Scholar
• Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004;22:2954-63
   PubMed Web of Science ®Google Scholar
• Application Number, Center for drug evaluation and research, office of clinical pharmacology 2003; 21-560s000
   Google Scholar
• Everolimus - Compound Summary (CID 6442177), National Center for Biotechnology Information, PubChem BioAssay Database
   Google Scholar
• Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004;43:83-95
   PubMed Web of Science ®Google Scholar
• O'Donnell A, Faivre S, Burris HA III, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008;26:1588-95
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Kahan BD, Kaplan B, et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther 2001;69:48-56
   PubMed Web of Science ®Google Scholar
• Jacobsen W, Serkova N, Hausen B, et al. Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. Transplant Proc 2001;33:514-15
   PubMed Web of Science ®Google Scholar
• Summary of Product Characteristics: Afinitor Tablets, Electronic Medicines Compendium; 2012
   Google Scholar
• Kovarik JM, Hartmann S, Figueiredo J, et al. Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Pharmacotherapy 2002;22:154-9
   PubMed Web of Science ®Google Scholar
• Amato RJ, Jac J, Giessinger S, et al. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009;115:2438-46
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 2010;116:4256-65
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56
   PubMed Web of Science ®Google Scholar
• Calvo E, Escudier B, Motzer RJ, et al. Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 2012;48:333-9
   PubMed Web of Science ®Google Scholar
• Bracarda S, Hutson TE, Porta C, et al. Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis. Br J Cancer 2012;106:1475-80
   PubMed Web of Science ®Google Scholar
• Porta C, Calvo E, Climent MA, et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol 2012;61:826-33
   PubMed Web of Science ®Google Scholar
• Stein A, Bellmunt J, Escudier B, et al. Survival Prediction in everolimus-treated Patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial. Eur Urol 2012
   Google Scholar
• Hainsworth JD, Spigel DR, Burris HA III, et al. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 2010;28:2131-6
   PubMed Web of Science ®Google Scholar
• Harzstark AL, Small EJ, Weinberg VK, et al. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer 2011;117:4194-200
   PubMed Web of Science ®Google Scholar
• Amato RJ, Flaherty AL, Stepankiw M. Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer. Clin Genitourin Cancer 2012;10:26-31
   PubMed Web of Science ®Google Scholar
• Molina AM, Feldman DR, Voss MH, et al. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 2012;118:1868-76
   PubMed Web of Science ®Google Scholar
• White DA, Camus P, Endo M, et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010;182:396-403
   PubMed Web of Science ®Google Scholar
• Ramirez-Fort MK, Case EC, Rosen AC, et al. Rash to the mTOR inhibitor Everolimus: systematic review and meta-analysis. Am J Clin Oncol 2012; Epub ahead of print
   Google Scholar
• Knox JJ, Kay AC, Schiff E, et al. First-line everolimus followed by second-line sunitinib versus the opposite treatment sequence in patients with metastatic renal cell carcinoma (mRCC) [abstract TPS232]. J Clin Oncol 2010;28(Suppl):15s
   PubMedGoogle Scholar